Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Benserazide→

Benserazide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
322-35-0
Molecular formula
C10H15N3O5
Molecular weight
257.24 g/mol
Drug class
Peripheral aromatic L-amino-acid (DOPA) decarboxylase inhibitor
Mechanism of action
Inhibits peripheral DOPA decarboxylase and does not appreciably enter the central nervous system. When co-administered with levodopa, it reduces peripheral conversion of levodopa to dopamine, increasing levodopa availability to the CNS and reducing the required levodopa dose. Benserazide alone has no antiparkinson activity.
Indications / reported uses
  • Used in combination with levodopa for Parkinsonism; benserazide is not an antiparkinson treatment by itself

Sources: NLM MeSH (Benserazide) · Health Canada product monograph listing for levodopa/benserazide

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Peripheral aromatic L-amino-acid (DOPA) decarboxylase inhibitor

Mechanism of action

Inhibits peripheral DOPA decarboxylase and does not appreciably enter the central nervous system. When co-administered with levodopa, it reduces peripheral conversion of levodopa to dopamine, increasing levodopa availability to the CNS and reducing the required levodopa dose. Benserazide alone has no antiparkinson activity.

General use cases

  • Used in combination with levodopa for Parkinsonism; benserazide is not an antiparkinson treatment by itself

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Benserazide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Benserazide Permitted Daily Exposure (PDE) report (the Benserazide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Benserazide Occupational Exposure Limit (OEL) report (the Benserazide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.